Melissa Desmedt1, Sonja Vertriest2, Johan Hellings3, Jochen Bergs4, Ezra Dessers5, Patrik Vankrunkelsven6, Hubertus Vrijhoef7, Lieven Annemans8, Nick Verhaeghe8, Mirko Petrovic9, Dominique Vandijck10. 1. Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium. Electronic address: melissa.desmedt@uhasselt.be. 2. Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium. 3. Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium; AZ Delta, Roeselare, Belgium. 4. Faculty of Business Economics, Hasselt University, Hasselt, Belgium. 5. Centre for Sociological Research, KU Leuven, Leuven, Belgium. 6. Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium. 7. Scientific Center for Care and Welfare, Tilburg University, Tilburg, The Netherlands; Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium; National University Singapore and National University Health System, Singapore. 8. Faculty of Medicine and Health Sciences, Interuniversity Centre for Health Economics Research (I-CHER), Ghent University, Ghent, Belgium. 9. Section of Geriatrics, Faculty of Medicine and Health Sciences, Department of Internal Medicine, Ghent University, Ghent, Belgium. 10. Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium; Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Abstract
OBJECTIVES: To assess the costs and potential financial benefits of integrated care models for patients with chronic diseases, that is, type 2 diabetes mellitus, schizophrenia, and multiple sclerosis, respectively. METHODS: A systematic search of the literature was performed using EMBASE, MEDLINE, and Web of Science. Studies that conducted a cost analysis, considered at least two components of the chronic care model, and compared integrated care with standard care were included. RESULTS: Out of 575 articles, 26 were included. Most studies examined integrated care models for type 2 diabetes mellitus (n = 18) and to a lesser extent for schizophrenia (n = 6) and multiple sclerosis (n = 2). Across the three disease groups, the incremental cost per patient per year ranged from - €3860 to + €613.91 (x¯ = - €533.61 ± €902.96). The incremental cost for type 2 diabetes mellitus ranged from - €1507.49 to + €299.20 (x¯ = - €518.22 ± + €604.75), for schizophrenia from - €3860 to + €613.91 (x¯ = - €677.21 ± + €1624.35), and for multiple sclerosis from - €822 to + €339.43 (x¯ = - €241.29 ± + €821.26). Most of the studies (22 of 26 [84.6%]) reported a positive economic impact of integrated care models: for type 2 diabetes mellitus (16 of 18 [88.9%]), schizophrenia (4 of 6 [66.7%]), and multiple sclerosis (1 of 2 [50%]). CONCLUSIONS: In this systematic literature review, predominantly positive economic impacts of integrated care models for patients with chronic diseases were found.
OBJECTIVES: To assess the costs and potential financial benefits of integrated care models for patients with chronic diseases, that is, type 2 diabetes mellitus, schizophrenia, and multiple sclerosis, respectively. METHODS: A systematic search of the literature was performed using EMBASE, MEDLINE, and Web of Science. Studies that conducted a cost analysis, considered at least two components of the chronic care model, and compared integrated care with standard care were included. RESULTS: Out of 575 articles, 26 were included. Most studies examined integrated care models for type 2 diabetes mellitus (n = 18) and to a lesser extent for schizophrenia (n = 6) and multiple sclerosis (n = 2). Across the three disease groups, the incremental cost per patient per year ranged from - €3860 to + €613.91 (x¯ = - €533.61 ± €902.96). The incremental cost for type 2 diabetes mellitus ranged from - €1507.49 to + €299.20 (x¯ = - €518.22 ± + €604.75), for schizophrenia from - €3860 to + €613.91 (x¯ = - €677.21 ± + €1624.35), and for multiple sclerosis from - €822 to + €339.43 (x¯ = - €241.29 ± + €821.26). Most of the studies (22 of 26 [84.6%]) reported a positive economic impact of integrated care models: for type 2 diabetes mellitus (16 of 18 [88.9%]), schizophrenia (4 of 6 [66.7%]), and multiple sclerosis (1 of 2 [50%]). CONCLUSIONS: In this systematic literature review, predominantly positive economic impacts of integrated care models for patients with chronic diseases were found.
Authors: Gemma Elizabeth Shields; Deborah Buck; Jamie Elvidge; Karen Petra Hayhurst; Linda Mary Davies Journal: Int J Technol Assess Health Care Date: 2019-07-22 Impact factor: 2.188
Authors: Maria C Prom; Victoria Canelos; Pedro J Fernandez; Katherine Gergen Barnett; Cindy M Gordon; Christine A Pace; Lauren C Ng Journal: J Behav Health Serv Res Date: 2020-11-25 Impact factor: 1.475
Authors: Patrick Timpel; Caroline Lang; Johan Wens; Juan Carlos Contel; Peter E H Schwarz Journal: Int J Integr Care Date: 2020-04-22 Impact factor: 5.120
Authors: Silvia Poveda-Moral; Pilar José-Maria de la Casa; Pere Sánchez-Valero; Núria Pomares-Quintana; Mireia Vicente-García; Anna Falcó-Pegueroles Journal: BMC Med Ethics Date: 2021-06-22 Impact factor: 2.652